Literature DB >> 2487686

Lymphocyte infiltration into cerebellum in transgenic mice carrying human IL-2 gene.

M Katsuki1, M Kimura, M Ohta, H Otani, O Tanaka, T Yamamoto, S Nozawa-Kimura, M Yokoyama, T Nomura, S Habu.   

Abstract

We created transgenic mice with an intact human genomic interleukin-2 gene (gIL-2) or a mouse metallothionein-I promoter-human IL-2 chimeric gene (MTgIL-2). Nine (2 gIL-2 and 7 MTgIL-2 transgenics) out of 12 transgenic mice which were obtained independently had motor ataxic symptoms. All transgenic offspring of the symptomatic founders showed the same symptoms as their transgenic parents. Morphological examination demonstrated perivascular lymphocyte accumulation in the cerebellar meninx which was followed by increased cell infiltration of neutrophils and monocytes in the destructive cerebellum of all transgenic mice. These findings suggest that the lymphocyte infiltration in the cerebellum is caused by the specific effect of the exogenously introduced human IL-2 gene.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2487686     DOI: 10.1093/intimm/1.2.214

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  4 in total

1.  The effect of neonatal tolerance to bovine gamma globulin (BGG) on BGG-reactive CD4+ T lymphocytes.

Authors:  S S Burtles; D C Hooper
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

2.  Lymphocyte infiltration of the skin in transgenic mice carrying the human interleukin-2 gene.

Authors:  M Akiyama; M Yokoyama; M Katsuki; S Habu; T Nishikawa
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

Review 3.  Analysis of the immune system with transgenic mice: B cell development and lymphokines.

Authors:  A Iglesias
Journal:  Experientia       Date:  1991-09-15

4.  Expression of the chemokine N51/KC in the thymus and epidermis of transgenic mice results in marked infiltration of a single class of inflammatory cells.

Authors:  S A Lira; P Zalamea; J N Heinrich; M E Fuentes; D Carrasco; A C Lewin; D S Barton; S Durham; R Bravo
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.